{"id":"NCT01788046","sponsor":"Amgen","briefTitle":"Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-12","primaryCompletion":"2014-04-14","completion":"2014-05-09","firstPosted":"2013-02-11","resultsPosted":"2017-03-27","lastUpdate":"2019-08-20"},"enrollment":515,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperparathyroidism, Secondary"],"interventions":[{"type":"DRUG","name":"Etelcalcetide","otherNames":["AMG 416"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Etelcalcetide","type":"EXPERIMENTAL"}],"summary":"This study is designed to assess the efficacy and safety of etelcalcetide (AMG 416) compared with placebo in the treatment of SHPT in CKD patients receiving hemodialysis.","primaryOutcome":{"measure":"Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase","timeFrame":"Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).","effectByArm":[{"arm":"Placebo","deltaMin":9.6,"sd":null},{"arm":"Etelcalcetide","deltaMin":75.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":106,"countries":["United States","Australia","Belgium","Canada","Czechia","France","Germany","Hungary","Israel","Italy","Netherlands","Poland","Russia","Spain","Sweden"]},"refs":{"pmids":["28097355","28274835","29392552","28803497","28508378","30875390","31317120","32082556","31199098"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":71,"n":259},"commonTop":["Blood calcium decreased","Diarrhoea","Muscle spasms","Nausea","Headache"]}}